Use of new imaging techniques to predict tumour response to therapy

The Lancet Oncology

Volumn 11, Issue 1, 2010, Pages 92-102

  Harry, Vanessa N ^a   Semple, Scott I ^b   Parkin, David E ^c   Gilbert, Fiona J ^d  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

^c ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^d UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; CONTRAST MEDIUM; FLUORODEOXYGLUCOSE F 18; GADOLINIUM; TAMOXIFEN;

ADJUVANT THERAPY; ADVANCED CANCER; APOPTOSIS; BRAIN TUMOR; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIFFUSION WEIGHTED IMAGING; DISEASE FREE SURVIVAL; DISEASE MARKER; DRUG RESPONSE; ELECTRON SPIN RESONANCE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; IMAGING SYSTEM; INTENSITY MODULATED RADIATION THERAPY; LIVER TUMOR; LUNG TUMOR; LYMPH NODE METASTASIS; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE CYCLE TREATMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHOTODYNAMIC THERAPY; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTON NUCLEAR MAGNETIC RESONANCE; RADIATION RESPONSE; RADIOFREQUENCY ABLATION; RECURRENCE RISK; REPRODUCIBILITY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STEREOTACTIC RADIOSURGERY; SURVIVAL RATE; TECHNIQUE; TREATMENT FAILURE; TREATMENT RESPONSE; TUMOR; TUMOR RECURRENCE; TUMOR VASCULARIZATION; UTERINE CERVIX CANCER; UTERINE CERVIX TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; CONTRAST MEDIA; DIAGNOSTIC IMAGING; DIFFUSION MAGNETIC RESONANCE IMAGING; ENDPOINT DETERMINATION; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; TREATMENT OUTCOME;

EID: 73249148919     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70190-1     Document Type: Review

References (88)

1. Heppner G.H., and Miller F.R. The cellular basis of tumor progression. Int Rev Cytol 177 (1998) 1-56
2. Pickles M.D., Gibbs P., Lowry M., and Turnbull L.W. Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. Magn Reson Imaging 24 (2006) 843-847
3. Padhani A.R. Functional MRI for anticancer therapy assessment. Eur J Cancer 38 (2002) 2116-2127
4. Chenevert T.L., Stegman L.D., Taylor J.M., et al. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 92 (2000) 2029-2036
5. Hamstra D.A., Rehemtulla A., and Ross B.D. Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol 25 (2007) 4104-4109
6. Chenevert T.L., McKeever P.E., and Ross B.D. Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging. Clin Cancer Res 3 (1997) 1457-1466
7. Galons J.P., Altbach M.I., Paine-Murrieta G.D., Taylor C.W., and Gillies R.J. Early increases in breast tumor xenograft water mobility in response to paclitaxel therapy detected by non-invasive diffusion magnetic resonance imaging. Neoplasia 1 (1999) 113-117
8. Mardor Y., Pfeffer R., Spiegelmann R., et al. Early detection of response to radiation therapy in patients with brain malignancies using conventional and high b-value diffusion-weighted magnetic resonance imaging. J Clin Oncol 21 (2003) 1094-1100
9. Moffat B.A., Chenevert T.L., Lawrence T.S., et al. Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci USA 102 (2005) 5524-5529
10. Hamstra D.A., Chenevert T.L., Moffat B.A., et al. Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci USA 102 (2005) 16759-16764
11. Mardor Y., Roth Y., Ochershvilli A., et al. Pretreatment prediction of brain tumors' response to radiation therapy using high b-value diffusion-weighted MRI. Neoplasia 6 (2004) 136-142
12. Tomura N., Narita K., Izumi J., et al. Diffusion changes in a tumor and peritumoral tissue after stereotactic irradiation for brain tumors: possible prediction of treatment response. J Comput Assist Tomogr 30 (2006) 496-500
13. Dzik-Jurasz A., Domenig C., George M., et al. Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet 360 (2002) 307-308
14. DeVries A.F., Kremser C., Hein P.A., et al. Tumor microcirculation and diffusion predict therapy outcome for primary rectal carcinoma. Int J Radiat Oncol Biol Phys 56 (2003) 958-965
15. Hein P.A., Kremser C., Judmaier W., et al. [Diffusion-weighted MRI-a new parameter for advanced rectal carcinoma?]. Rofo 175 (2003) 381-386 (in German).
16. Kremser C., Judmaier W., Hein P., et al. Preliminary results on the influence of chemoradiation on apparent diffusion coefficients of primary rectal carcinoma measured by magnetic resonance imaging. Strahlenther Onkol 179 (2003) 641-649
17. Theilmann R.J., Borders R., Trouard T.P., et al. Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. Neoplasia 6 (2004) 831-837
18. Uhl M., Saueressig U., Koehler G., et al. Evaluation of tumour necrosis during chemotherapy with diffusion-weighted MR imaging: preliminary results in osteosarcomas. Pediatr Radiol 36 (2006) 1306-1311
19. Lee K.C., Bradley D.A., Hussain M., et al. A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. Neoplasia 9 (2007) 1003-1011
20. Kamel I.R., Bluemke D.A., Eng J., et al. The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma. J Vasc Interv Radiol 17 (2006) 505-512
21. Sugahara T., Korogi Y., Kochi M., et al. Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging 9 (1999) 53-60
22. Hayashida Y., Yakushiji T., Awai K., et al. Monitoring therapeutic responses of primary bone tumors by diffusion-weighted image: initial results. Eur Radiol 16 (2006) 2637-2643
23. Thoeny H.C., De Keyzer F., Chen F., et al. Diffusion-weighted magnetic resonance imaging allows noninvasive in vivo monitoring of the effects of combretastatin a-4 phosphate after repeated administration. Neoplasia 7 (2005) 779-787
24. Ross B.D., Chenevert T.L., Kim B., and Ben-Yoseph O. Magnetic resonance imaging and spectroscopy: application to experimental neuro-oncology. Q Magn Reson Biol Med 1 (1994) 89-106
25. Hein P.A., Kremser C., Judmaier W., et al. Diffusion-weighted magnetic resonance imaging for monitoring diffusion changes in rectal carcinoma during combined, preoperative chemoradiation: preliminary results of a prospective study. Eur J Radiol 45 (2003) 214-222
26. Chinnaiyan A.M., Prasad U., Shankar S., et al. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci USA 97 (2000) 1754-1759
27. Uhl M., Altehoefer C., Kontny U., et al. MRI-diffusion imaging of neuroblastomas: first results and correlation to histology. Eur Radiol 12 (2002) 2335-2338
28. Manenti G., Squillaci E., Di Roma M., et al. In vivo measurement of the apparent diffusion coefficient in normal and malignant prostatic tissue using thin-slice echo-planar imaging. Radiol Med (Torino) 111 (2006) 1124-1133
29. Harry V.N., Semple S.I., Gilbert F.J., and Parkin D.E. Diffusion-weighted magnetic resonance imaging in the early detection of response to chemoradiation in cervical cancer. Gynecol Oncol 111 (2008) 213-220
30. Tofts P.S., and Kermode A.G. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med 17 (1991) 357-367
31. Pickles M.D., Lowry M., Manton D.J., Gibbs P., and Turnbull L.W. Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy. Breast Cancer Res Treat 91 (2005) 1-10
32. Nagashima T., Sakakibara M., Nakamura R., et al. Dynamic enhanced MRI predicts chemosensitivity in breast cancer patients. Eur J Radiol 60 (2006) 270-274
33. George M.L., Dzik-Jurasz A.S., Padhani A.R., et al. Non-invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer. Br J Surg 88 (2001) 1628-1636
34. DeVries A., Griebel J., Judmaier W., et al. Perfusion-index values evaluated by dynamic magnetic resonance imaging in advanced rectal carcinoma. A new predictor of response to preoperative radiochemotherapy?. Strahlenther Onkol 176 (2000) 567-572
35. Tomura N., Omachi K., Sakuma I., et al. Dynamic contrast-enhanced magnetic resonance imaging in radiotherapeutic efficacy in the head and neck tumors. Am J Otolaryngol 26 (2005) 163-167
36. Weber M.A., Thilmann C., Lichy M.P., et al. Assessment of irradiated brain metastases by means of arterial spin-labelling and dynamic susceptibility-weighted contrast-enhanced perfusion MRI: initial results. Invest Radiol 39 (2004) 277-287
37. Tomoi M., Maeda M., Yoshida M., et al. Assessment of radiotherapeutic effect on brain tumors by dynamic susceptibility contrast MR imaging: a preliminary report. Radiat Med 17 (1999) 195-199
38. Gong Q.Y., Brunt J.N., Romaniuk C.S., et al. Contrast enhanced dynamic MRI of cervical carcinoma during radiotherapy: early prediction of tumour regression rate. Br J Radiol 72 (1999) 1177-1184
39. Hawighorst H., Weikel W., Knapstein P.G., et al. Angiogenic activity of cervical carcinoma: assessment by functional magnetic resonance imaging-based parameters and a histomorphological approach in correlation with disease outcome. Clin Cancer Res 4 (1998) 2305-2312
40. Mayr N.A., Yuh W.T., Arnholt J.C., et al. Pixel analysis of MR perfusion imaging in predicting radiation therapy outcome in cervical cancer. J Magn Reson Imaging 12 (2000) 1027-1033
41. Mayr N.A., Yuh W.T., Magnotta V.A., et al. Tumor perfusion studies using fast magnetic resonance imaging technique in advanced cervical cancer: a new noninvasive predictive assay. Int J Radiat Oncol Biol Phys 36 (1996) 623-633
42. Loncaster J.A., Carrington B.M., Sykes J.R., et al. Prediction of radiotherapy outcome using dynamic contrast enhanced MRI of carcinoma of the cervix. Int J Radiat Oncol Biol Phys 54 (2002) 759-767
43. Boss E.A., Massuger L.F., Pop L.A., et al. Post-radiotherapy contrast enhancement changes in fast dynamic MRI of cervical carcinoma. J Magn Reson Imaging 13 (2001) 600-606
44. Mayr N.A., Yuh W.T., Zheng J., et al. Prediction of tumor control in patients with cervical cancer: analysis of combined volume and dynamic enhancement pattern by MR imaging. AJR Am J Roentgenol 170 (1998) 177-182
45. Yamashita Y., Baba T., Baba Y., et al. Dynamic contrast-enhanced MR imaging of uterine cervical cancer: pharmacokinetic analysis with histopathologic correlation and its importance in predicting the outcome of radiation therapy. Radiology 216 (2000) 803-809
46. Ohno Y., Nogami M., Higashino T., et al. Prognostic value of dynamic MR imaging for non-small-cell lung cancer patients after chemoradiotherapy. J Magn Reson Imaging 21 (2005) 775-783
47. Barentsz J.O., Berger-Hartog O., Witjes J.A., et al. Evaluation of chemotherapy in advanced urinary bladder cancer with fast dynamic contrast-enhanced MR imaging. Radiology 207 (1998) 791-797
48. Padhani A.R., and Leach M.O. Antivascular cancer treatments: functional assessments by dynamic contrast-enhanced magnetic resonance imaging. Abdom Imaging 30 (2005) 324-341
49. Liu G., Rugo H.S., Wilding G., et al. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol 23 (2005) 5464-5473
50. Wedam S.B., Low J.A., Yang S.X., et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 24 (2006) 769-777
51. Zhao M., Pipe J.G., Bonnett J., and Evelhoch J.L. Early detection of treatment response by diffusion-weighted 1H-NMR spectroscopy in a murine tumour in vivo. Br J Cancer 73 (1996) 61-64
52. Manton D.J., Chaturvedi A., Hubbard A., et al. Neoadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopy. Br J Cancer 94 (2006) 427-435
53. Meisamy S., Bolan P.J., Baker E.H., et al. Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1)H MR spectroscopy-a pilot study at 4 T. Radiology 233 (2004) 424-431
54. Wu B., Peng W.J., Wang P.J., et al. In vivo 1H magnetic resonance spectroscopy in evaluation of hepatocellular carcinoma and its early response to transcatheter arterial chemoembolization. Chin Med Sci J 21 (2006) 258-264
55. Schwarz A.J., Maisey N.R., Collins D.J., et al. Early in vivo detection of metabolic response: a pilot study of 1H MR spectroscopy in extracranial lymphoma and germ cell tumours. Br J Radiol 75 (2002) 959-966
56. Preul M.C., Caramanos Z., Villemure J.G., et al. Using proton magnetic resonance spectroscopic imaging to predict in vivo the response of recurrent malignant gliomas to tamoxifen chemotherapy. Neurosurgery 46 (2000) 306-318
57. Shukla-Dave A., Poptani H., Loevner L.A., et al. Prediction of treatment response of head and neck cancers with P-31 MR spectroscopy from pretreatment relative phosphomonoester levels. Acad Radiol 9 (2002) 688-694
58. Arias-Mendoza F., Smith M.R., and Brown T.R. Predicting treatment response in non-Hodgkin's lymphoma from the pretreatment tumor content of phosphoethanolamine plus phosphocholine. Acad Radiol 11 (2004) 368-376
59. Young H., Baum R., Cremerius U., et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35 (1999) 1773-1782
60. Downey R.J., Akhurst T., Gonen M., Park B., and Rusch V. Fluorine-18 fluorodeoxyglucose positron emission tomographic maximal standardized uptake value predicts survival independent of clinical but not pathologic TNM staging of resected non-small cell lung cancer. J Thorac Cardiovasc Surg 133 (2007) 1419-1427
61. Eschmann S.M., Friedel G., Paulsen F., et al. 18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer. Eur J Nucl Med Mol Imaging 34 (2007) 463-471
62. Pottgen C., Levegrun S., Theegarten D., et al. Value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res 12 (2006) 97-106
63. Weber W.A., Petersen V., Schmidt B., et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 21 (2003) 2651-2657
64. Zhang Z.J., Chen J.H., Meng L., et al. 18F-FDG uptake as a biologic factor predicting outcome in patients with resected non-small-cell lung cancer. Chin Med J (Engl) 120 (2007) 125-131
65. Ott K., Fink U., Becker K., et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol 21 (2003) 4604-4610
66. Rizk N., Downey R.J., Akhurst T., et al. Preoperative 18[F]-fluorodeoxyglucose positron emission tomography standardized uptake values predict survival after oesophageal adenocarcinoma resection. Ann Thorac Surg 8 (2006) 1076-1081
67. Swisher S.G., Erasmus J., Maish M., et al. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer 101 (2004) 1776-1785
68. Hong D., Lunagomez S., Kim E.E., et al. Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma. Cancer 104 (2005) 1620-1626
69. Kim M.K., Ryu J.S., Kim S.B., et al. Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy. Eur J Cancer 43 (2007) 1385-1391
70. Weber W.A., Ott K., Becker K., et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19 (2001) 3058-3065
71. Hatano E., Ikai I., Higashi T., et al. Preoperative positron emission tomography with fluorine-18-fluorodeoxyglucose is predictive of prognosis in patients with hepatocellular carcinoma after resection. World J Surg 30 (2006) 1736-1741
72. Rousseau C., Devillers A., Sagan C., et al. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography. J Clin Oncol 24 (2006) 5366-5372
73. Li D., Chen J.H., Wang J., et al. Value of fused 18F-FDG PET/CT images in predicting efficacy of neoadjuvant chemotherapy on breast cancer. Ai Zheng 26 (2007) 900-904
74. Allal A.S., Dulguerov P., Allaoua M., et al. Standardized uptake value of 2-[(18)F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol 20 (2002) 1398-1404
75. Schwartz D.L., Rajendran J., Yueh B., et al. FDG-PET prediction of head and neck squamous cell cancer outcomes. Arch Otolaryngol Head Neck Surg 130 (2004) 1361-1367
76. Kidd E.A., Siegel B.A., Dehdashti F., and Grigsby P.W. The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer 110 (2007) 1738-1744
77. Xue F., Lin L.L., Dehdashti F., et al. F-18 fluorodeoxyglucose uptake in primary cervical cancer as an indicator of prognosis after radiation therapy. Gynecol Oncol 101 (2006) 147-151
78. Gallamini A., Rigacci L., Merli F., et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 91 (2006) 475-481
79. Eschmann S.M., Friedel G., Paulsen F., et al. Is standardised (18)F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer?. Eur J Nucl Med Mol Imaging 33 (2006) 263-269
80. Grigsby P.W., Siegel B.A., and Dehdashti F. Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol 19 (2001) 3745-3749
81. Downey R.J., Akhurst T., Gonen M., et al. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 22 (2004) 3255-3260
82. Sasaki R., Komaki R., Macapinlac H., et al. [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 23 (2005) 1136-1143
83. McDermott G.M., Welch A., Staff R.T., et al. Monitoring primary breast cancer throughout chemotherapy using FDG-PET. Breast Cancer Res Treat 102 (2007) 75-84
84. Semple S.I., Staff R.T., Heys S.D., et al. Baseline MRI delivery characteristics predict change in invasive ductal breast carcinoma PET metabolism as a result of primary chemotherapy administration. Ann Oncol 17 (2006) 1393-1398
85. Semple S.I., Gilbert F.J., Redpath T.W., et al. The relationship between vascular and metabolic characteristics of primary breast tumours. Eur Radiol 14 (2004) 2038-2045
86. Rockall A.G., Sohaib S.A., Harisinghani M.G., et al. Diagnostic performance of nanoparticle-enhanced magnetic resonance imaging in the diagnosis of lymph node metastases in patients with endometrial and cervical cancer. J Clin Oncol 23 (2005) 2813-2821
87. Padhani A.R. Where are we with imaging oxygenation in human tumours?. Cancer Imaging 5 (2005) 128-130
88. Hicks R.J., Rischin D., Fisher R., et al. Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent. Eur J Nucl Med Mol Imaging 32 (2005) 1384-1391